Court Rules Roche Drug Doesn’t Infringe Patent
- Share via
Bloomberg News
Roche Holding, Europe’s fifth-largest drug maker, said a German court has ruled that its breast cancer medicine Herceptin does not infringe a Chiron Corp. patent.
Emeryville-based Chiron filed the lawsuit against Roche in February 2001, claiming the Swiss firm infringed a patent regarding mouse monoclonal antibodies. Herceptin was Roche’s sixth-best-selling drug last year with sales of $502 million.
Shares of Chiron rose 91 cents to $39.50 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
